D-peptide 1 effectively suppressed tumor growth and stemness in vitro and in vivo potentially by modulating pGSN or other PPI binding without complete disruption, underscoring the therapeutic potential of targeting the DCLK1 NKEBD. Here, DCLK1 is linked to neoplasm.